CLAIMS

1. An aqueous liquid comprising an aptamer or a salt thereof that binds to FGF2, and a non-electrolytic osmoregulator, wherein the aptamer or a salt thereof is stable for a long term.

2. The aqueous liquid according to claim 1, wherein the liquid is substantially free of an electrolyte other than the aptamer or a salt thereof.

3. The aqueous liquid according to claim 1, wherein the aptamer comprises a nucleotide sequence represented by the following formula (1) (wherein uracil is optionally thymine):

$N^1GGAN^2ACUAGGGCN^3UUAAN^4GUN^5ACCAGUGUN^6$ (1)

(wherein N^1 and N^6 are each independently any 0 to several bases, and

N^2, N^3, N^4 and N^5 are independently any one base),

and is the following (a) or (b):

(a) an aptamer wherein, in the nucleotides contained in the aptamer,

(i) the 2'-position of the ribose of each pyrimidine nucleotide is a fluorine atom,

(ii) the 2'-position of the ribose of each purine nucleotide is a hydroxy group;

(b) the aptamer of (a), wherein

(i) the fluorine atom at the 2'-position of the ribose of each pyrimidine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a hydroxy group and a methoxy group,

(ii) the hydroxy group at the 2'-position of the ribose of each purine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a methoxy group and a fluorine atom.

4. The aqueous liquid according to claim 1 or 2, wherein the aptamer comprises a nucleotide sequence represented by the following formula (3):

N^1GGAUACUAGGGCAUUAAUGUUACCAGUGUAGUCN^{62} (3)

(wherein N^1 and N^{62} are each independently any 0 to several bases).

5. The aqueous liquid according to claim 1 or 2, wherein the aptamer comprises a nucleotide sequence shown in SEQ ID NO: 3, 8, 9, 10 or 12.

6. The aqueous liquid according to any one of claims 1 to 5, wherein the aptamer has a concentration of 1 - 60 mg/mL.

7. The aqueous liquid according to any one of claims 1 to 6, wherein the osmoregulator is blended at a proportion of 2 - 7.5%(w/v) of the whole aqueous liquid.

8. The aqueous liquid according to any one of claims 1 to 7, wherein the osmoregulator is mannitol.

9. The aqueous liquid according to claim 8, wherein the mannitol is contained at 1 - 50 mg per 1 mg of the aptamer.

10. The aqueous liquid according to any one of claims 1 to 9, wherein the liquid is stored at not more than 5°C.

11. The aqueous liquid according to any one of claims 1 to 10, wherein a proportion of a monomer aptamer is not less than 80% after storage at 4°C for 3 months.

12. The aqueous liquid according to any one of claims 1 to 11, wherein the liquid is an injection.

13. The aqueous liquid according to any one of claims 1 to 12, wherein the liquid is for preventing or treating a disease accompanied by angiogenesis, bone or cartilage disease or pain.

~~14. A method for preventing or treating a disease accompanied by angiogenesis, bone or cartilage disease or pain, comprising administering the aqueous liquid according to any one of claims 1 to 12 to a subject.~~

~~15~~14. The aqueous liquid according to any one of claims 1 to 12 for use in the prophylaxis or treatment of a disease accompanied by angiogenesis, bone or cartilage disease or pain.